Bisphosphonates intake and its association with changes of periarticular bone area and three-dimensional shape: data from the osteoarthritis initiative (OAI)

Haj‐Mirzaian, Arya; Guermazi, Ali; Roemer, Frank W.; Bowes, M.; Conaghan, P. G.; Demehri, Shadpour

doi:10.1016/j.joca.2018.02.612

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, extensive sensitivity analyses showed conclusions were unchanged when accounting for potential residual confounding, healthy-user bias, or exposure misclassification. This study adds to previous research demonstrating protective effects of bisphosphonates for certain knee OA outcomes, including potential protection from joint space changes (33) and pain outcomes. (11) However, these studies did not take advantage of time-to-event data, instead using hypothesis testing methods to compare JSN (11,33) and pain outcomes.…”

Section: Discussionmentioning

confidence: 60%

“…This study adds to previous research demonstrating protective effects of bisphosphonates for certain knee OA outcomes, including potential protection from joint space changes (33) and pain outcomes. (11) However, these studies did not take advantage of time-to-event data, instead using hypothesis testing methods to compare JSN (11,33) and pain outcomes. (11) Previous work also did not investigate KL progression, which includes a number of osseous features such as osteophytosis and attrition that could reflect bone remodeling of the knee and which may be affected by bisphosphonate effects on subchondral bone.…”

Section: Discussionmentioning

confidence: 60%

“…Our results may partially elucidate why results differ between trials, observational studies, and meta-analyses (5,(11)(12)(13)(14)(15)(16)33) examining the benefit of bisphosphonates for various radiographic and symptomatic outcomes. Prior to examining effects, it is Weighted by stabilized and truncated (at the 5th and 95th percentile) inverse probability censor weights.…”

Section: Discussionmentioning

confidence: 86%

“…Our results may partially elucidate why results differ between trials, observational studies, and meta‐analyses ( 5,11–16,33 ) examining the benefit of bisphosphonates for various radiographic and symptomatic outcomes. Prior to examining effects, it is necessary to understand the interplay of OA risk factors, the potential mechanism of benefit that bisphosphonates may have, and in which populations these protective effects would demonstrate the most benefit.…”

Section: Discussionmentioning

confidence: 88%

See 3 more Smart Citations

Bisphosphonate Use Is Protective of Radiographic Knee Osteoarthritis Progression Among those With Low Disease Severity and Being Non-Overweight: Data From the Osteoarthritis Initiative

Hayes

Giannakeas

Wong

2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Antiresorptive medications have been explored for treating knee osteoarthritis (OA); however, little data exist on the effects of today's more potent nitrogen‐containing oral bisphosphonates on radiographic disease‐progression in patients with varying disease‐severity, especially those who are not overweight. The primary objective of this cohort study was to determine if the use of bisphosphonates is protective against 2‐year radiographic‐progression of knee OA in Osteoarthritis Initiative (OAI) participants, stratified by baseline radiographic disease status. Secondary objectives were to examine effects in non‐overweight participants (body mass index [BMI] < 25 kg/m2) and cumulative bisphosphonate exposure effects. We identified female OAI participants aged ≥50 years and excluded those missing baseline radiograph readings, bisphosphonate use information, or all clinical questionnaire information at baseline. Participants reporting bisphosphonate use (69% alendronate) were propensity‐matched 1:1 to non–bisphosphonate users and followed until first radiographic knee OA progression (1‐unit increase in Kellgren and Lawrence [KL] grade) or data were censored (first missed visit or end of 2‐year follow‐up). Discrete‐time logistic regression models estimated hazard ratios (HRs) between bisphosphonate users versus nonusers, with an interaction term for baseline KL grade (KL <2 or KL ≥2). We identified 1977 eligible women (n = 346 bisphosphonate users). Propensity‐matched results indicated that bisphosphonate users with KL grade <2 were protected against progression (HRKL<2 0.53; 95% CI, 0.35 to 0.79), while bisphosphonate use was not associated with radiographic progression in those with KL grade ≥2 (HRKL≥2 1.06; 95% CI, 0.83 to 1.35). When restricting analyses to those with BMI <25 kg/m2, effects were strengthened (HRKL<2 0.49 [95% CI, 0.26 to 0.92]; HRKL≥2 0.69 [95% CI, 0.33 to 1.26]). Duration of bisphosphonate use had no effect on progression, though sample size was limited. Bisphosphonate therapy may be protective against radiographic knee OA progression in early‐stage patients, particularly those who are non‐overweight, but less so for those with more advanced disease or more weight‐bearing joint stress. © 2020 American Society for Bone and Mineral Research (ASBMR).

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 88%

See 2 more Smart Citations

Bisphosphonate Use Is Protective of Radiographic Knee Osteoarthritis Progression Among those With Low Disease Severity and Being Non-Overweight: Data From the Osteoarthritis Initiative

Hayes

Giannakeas

Wong

2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…Women had a higher risk of knee OA incidence than men, with the observed difference partially mediated by differences in bone shape 49 . A study by Haj-Mirzaian et al involving 152 women with knee OA from the OAI showed that bisphosphonate use was associated with a smaller increase in medial tibia bone area over a 24 month follow-up period 50 .…”

Section: Bone In Knee Oamentioning

confidence: 99%

Osteoarthritis year in review 2019: imaging

Kijowski

Demehri

Roemer

et al. 2020

Osteoarthritis and Cartilage

Self Cite

View full text Add to dashboard Cite

PET-MRI". Articles were reviewed to determine relevance based upon the following criteria: 1) study involved human subjects with OA or risk factors for OA and 2) study involved imaging to evaluate OA disease status or OA treatment response. Relevant articles were ranked according to scientific merit, with the best publications selected for inclusion in the narrative report. Results: The PubMed search revealed a total of 1257 articles, of which 256 (20.4%) were considered relevant to OA imaging. Two-hundred twenty-six (87.1%) articles involved the knee joint, while 195 (76.2%) articles involved the use of magnetic resonance imaging (MRI). The proportion of published studies involving the use of MRI was higher than previous years. An increasing number of articles were also published on imaging of subjects with joint injury and on deep learning application in OA imaging. Conclusion: MRI and other imaging modalities continue to play an important role in research studies designed to better understand the pathogenesis, progression, and treatment of OA.

show abstract

Senescent Preosteoclast Secretome Promotes Metabolic Syndrome-Associated Osteoarthritis through Cyclooxygenase 2

Wan

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Metabolic syndrome–associated osteoarthritis (MetS-OA) is a distinct osteoarthritis phenotype defined by the coexistence of MetS or its individual components. Despite the high prevalence of MetS-OA, its pathogenic mechanisms are unclear. The aim of this study was to determine the role of cellular senescence in the development of MetS-OA. Methods: Analysis of the human osteoarthritis initiative (OAI) dataset was conducted to investigate the MRI subchondral bone features of MetS-human OA participants. Joint phenotype and senescent cells were evaluated in two MetS-OA mouse models: high-fat diet (HFD)-challenged mice and STR/Ort mice. In addition, the molecular mechanisms by which preosteoclasts become senescent as well as how the senescent preosteoclasts impair subchondral bone microenvironment were characterized using in vitro preosteoclast culture system. Results: Humans and mice with MetS are more likely to develop osteoarthritis-related subchondral bone alterations than those without MetS. MetS-OA mice exhibited a rapid increase in joint subchondral bone plate and trabecular thickness before articular cartilage degeneration. Subchondral preosteoclasts undergo senescence at the pre- or early-osteoarthritis stage and acquire a unique secretome to stimulate osteoblast differentiation and inhibit osteoclast differentiation. Antagonizing preosteoclast senescence markedly mitigates pathological subchondral alterations and osteoarthritis progression in MetS-OA mice. At the molecular level, preosteoclast secretome activates COX2-PGE2, resulting in stimulated differentiation of osteoblast progenitors for subchondral bone formation. Administration of a selective COX2 inhibitor attenuated subchondral bone alteration and osteoarthritis progression in MetS-OA mice. Longitudinal analyses of the human Osteoarthritis Initiative (OAI) cohort dataset also revealed that COX2 inhibitor use, relative to non-selective nonsteroidal anti-inflammatory drug use, is associated with less progression of osteoarthritis and subchondral bone marrow lesion worsening in participants with MetS-OA. Conclusions: Our findings suggest a central role of a senescent preosteoclast secretome-COX2/PGE2 axis in the pathogenesis of MetS-OA, in which selective COX2 inhibitors may have disease-modifying potential. Funding: This work was supported by the National Institutes of Health grant R01AG068226 and R01AG072090 to M.W., R01AR079620 to S.D., and P01AG066603 to X.C.

show abstract

Bisphosphonates intake and its association with changes of periarticular bone area and three-dimensional shape: data from the osteoarthritis initiative (OAI)

Cited by 3 publications

References 0 publications

Bisphosphonate Use Is Protective of Radiographic Knee Osteoarthritis Progression Among those With Low Disease Severity and Being Non-Overweight: Data From the Osteoarthritis Initiative

Bisphosphonate Use Is Protective of Radiographic Knee Osteoarthritis Progression Among those With Low Disease Severity and Being Non-Overweight: Data From the Osteoarthritis Initiative

Osteoarthritis year in review 2019: imaging

Senescent Preosteoclast Secretome Promotes Metabolic Syndrome-Associated Osteoarthritis through Cyclooxygenase 2

Contact Info

Product

Resources

About